A water channel in cells is associated with breast cancer that behaves more aggressively. The striking part is not just where this channel appears, but what its presence predicts about the disease. Aquaporin five, or AQP five, is an aquaporin water channel whose expression was studied in breast cancer tissue, with overexpression observed in thirty-six percent of five hundred ninety-one cases.

In breast cancer, AQP five positivity was associated with less favorable cancer-specific survival over seven years, suggesting that its presence may carry information about how the disease behaves. The study examined five hundred ninety-one breast cancer tissue samples and found AQP five overexpression in thirty-six percent, then assessed clinicopathologic features in tumors with especially strong expression, defined as three-plus, comprising sixty cases.

The central pattern was clear: strong AQP5 expression was linked with higher tumor grade, appeared more often in certain hormone-negative cancers, and was associated with less favorable breast cancer-specific survival over seven years. The investigation examined AQP5 expression in resected breast cancer samples and focused on tumors with high AQP5 levels and their clinical characteristics.

The study also used seven years of follow-up data to examine what overall AQP5 expression might mean for prognosis, and examined gene amplification as one possible cause of strong expression. The conclusion was that some breast cancers with strong AQP5 expression are likely driven by extra copies of the AQP5 gene.

The breast tissue came from patients whose participation had been approved and documented with written consent, and the data were fully anonymized before use. The samples were collected between January nineteen ninety-three and December nineteen ninety-eight, and representative tumor areas were arranged to reduce tissue loss and account for differences within tumors.

This tissue staining makes the central question visible: breast cancers contain widely varying amounts of AQP5, from barely detectable to strong, while the comparison tissue provides a familiar reference for interpreting that range. Strong AQP5 expression was more common in hormone-receptor-negative breast cancers than in hormone-receptor-positive cancers, while a HER2-positive status was positively correlated with strong AQP5 expression.

The study included seven men with breast cancer, but the number was too small to interpret gender differences in clinicopathological characteristics reliably. A marker found in some breast cancers identified people whose chance of surviving the cancer was worse over time.

This difference was unlikely to be due to chance, with a probability of zero point zero zero eight. The patients were followed for overall survival for up to seven years after diagnosis, and the group with positive AQP5 expression had less favorable breast cancer-specific survival.

The study also found evidence that the AQP5 gene had been copied more than usual in some breast cancer cases. This suggests that extra gene copies may help explain strong AQP5 expression in at least some tumors. AQP5 expression was linked with higher-grade breast cancer and less favorable cancer-specific survival, while some strong expression was tied to extra copies of its gene.

That may help identify patients whose tumors need closer attention.